April 20, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Yamanouchi Pharmaceutical to Transfer All Sanwell Shares to Asahi Breweries
 

Tokyo, Feb 2, 2005 (JCN) - Yamanouchi Pharmaceutical (TSE: 4503) has announced that it has decided to transfer the entire outstanding shares of Sanwell, its wholly owned subsidiary in health food business, to Asahi Breweries.

Through this transfer of shares, Yamanouchi aims to concentrate its management resources on the ethical pharmaceutical operations and strengthen its whole business.

The transfer is scheduled to be completed by the end of March.

By Aki Tsukioka Contributor

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Yamanouchi Pharmaceutical Co., Ltd. News  
  Mega Pharmaceutical Astellas Pharma Kicks Off Operations  (Apr 1, 2005)
  Yamanouchi Pharmaceutical, Keio University Discover Target Molecule for Anti-obesity and Antidiabetic Drug  (Mar 25, 2005)
  Yamanouchi Terminates Marketing Agreement with Daiichi Suntory Pharma  (Feb 18, 2005)
  Yamanouchi Pharmaceutical to License Gelpart Coronary Embolism Material to Nippon Kayaku  (Feb 9, 2005)
  Yamanouchi Pharmaceutical to Transfer All Sanwell Shares to Asahi Breweries  (Feb 2, 2005)
  Lipitor, Atorvastatin Calcium Hydrate Greatly Inhibits Coronary Artery Plaque Progression: Yamanouchi Pharmaceutical, Pfizer Japan  (Jan 31, 2005)
  Yamanouchi Pharmaceutical, RIKEN Shed Light on Genetic Network of Biological Clock  (Jan 25, 2005)
  Yamanouchi to Market Vesicare for Treatment of Overactive Bladder in US  (Jan 21, 2005)
  Yamanouchi to Spin Off Formulation Plants  (Nov 10, 2004)
  Yamanouchi Obtains Approval for an Additional Dosage Form Using Its Proprietary OCAS Technology for Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in the Netherlands  (Sept 22, 2004)



 Recent  Drugs & OTC News   
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)
Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America (July 26, 2013)
Takara Bio launches Nippi's iMatrix-511 Worldwide (July 12, 2013)
Furukawa Electric Develops Quartz Dot Test Kit to Detect Acanthamoeba (July 10, 2013)
Takara Bio Grants Cellular Dynamics a Commercial License to Use RetroNectin for iPSC Production (June 24, 2013)

More Drugs & OTC news...

 Recent  Drugs & OTC News   
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)
Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America (July 26, 2013)
Takara Bio launches Nippi's iMatrix-511 Worldwide (July 12, 2013)
Furukawa Electric Develops Quartz Dot Test Kit to Detect Acanthamoeba (July 10, 2013)
Takara Bio Grants Cellular Dynamics a Commercial License to Use RetroNectin for iPSC Production (June 24, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)